retatrutide nonalcoholic fatty liver disease trial was alleviated by Lilly's 'triple-G' obesity drug Triple hormone receptor agonist retatrutide

(US) Orgain (US) Premier Nutrition (US) Perfect Day (US) Key Industry Developments June 2026: Nestl Health Science expanded its nutrition and wellness portfolio with new metabolic health solutions designed to support weight management and healthy lifestyle goals

They are licensed to ship nationwide, including Puerto Rico

Practical considerations such as injection frequency, needle size, and gastrointestinal tolerability may also influence individual patient selection

Patients with favorable genetic profiles may achieve weight loss goals at lower doses, reducing side effects and monthly costs

Note: Medicare beneficiaries wishing to receive a GLP-1 for weight loss alone without a related risk factor will not be eligible for savings under the GENEROUS model

Toward a broader response to cardiometabolic disease